Frontiers in Immunology (Jul 2023)
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
- Nicole L. Messina,
- Nicole L. Messina,
- Mariana G. Sperotto,
- Mariana G. Sperotto,
- Marco A. M. Puga,
- Marco A. M. Puga,
- Patricia V. da Silva,
- Patricia V. da Silva,
- Roberto D. de Oliveira,
- Roberto D. de Oliveira,
- Cecilia L. Moore,
- Laure F. Pittet,
- Laure F. Pittet,
- Laure F. Pittet,
- Tenaya Jamieson,
- Margareth Dalcolmo,
- Margareth Dalcolmo,
- Glauce dos Santos,
- Bruno Jardim,
- Marcus V. G. Lacerda,
- Nigel Curtis,
- Nigel Curtis,
- Nigel Curtis,
- Julio Croda,
- Julio Croda,
- Julio Croda
Affiliations
- Nicole L. Messina
- Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children’s Research Institute, Parkville, VIC, Australia
- Nicole L. Messina
- Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
- Mariana G. Sperotto
- School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Mariana G. Sperotto
- Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Marco A. M. Puga
- School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Marco A. M. Puga
- Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Patricia V. da Silva
- School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Patricia V. da Silva
- Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Roberto D. de Oliveira
- State University of Mato Grosso do Sul, Dourados-Mato Grosso do Sul, Brazil
- Roberto D. de Oliveira
- Federal University of Grande Dourados, Dourados, Brazil
- Cecilia L. Moore
- Clinical Epidemiology and Biostatistics Unit, Murdoch Children’s Research Institute, Parkville, VIC, Australia
- Laure F. Pittet
- Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children’s Research Institute, Parkville, VIC, Australia
- Laure F. Pittet
- Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
- Laure F. Pittet
- Infectious Diseases, The Royal Children’s Hospital Melbourne, Parkville, VIC, Australia
- Tenaya Jamieson
- Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children’s Research Institute, Parkville, VIC, Australia
- Margareth Dalcolmo
- Helio Fraga Reference Center, Oswaldo Cruz Foundation Ministry of Health, Rio de Janeiro, Rio de Janeiro, Brazil
- Margareth Dalcolmo
- 0Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
- Glauce dos Santos
- 1National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil
- Bruno Jardim
- 2Institute of Clinical Research Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil
- Marcus V. G. Lacerda
- 2Institute of Clinical Research Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil
- Nigel Curtis
- Infectious Diseases Group, Infection and Immunity Theme, Murdoch Children’s Research Institute, Parkville, VIC, Australia
- Nigel Curtis
- Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
- Nigel Curtis
- Infectious Diseases, The Royal Children’s Hospital Melbourne, Parkville, VIC, Australia
- Julio Croda
- School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Julio Croda
- Oswaldo Cruz Foundation Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
- Julio Croda
- 3Yale School of Public Health, New Haven, CT, United States
- DOI
- https://doi.org/10.3389/fimmu.2023.1172851
- Journal volume & issue
-
Vol. 14
Abstract
Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.
Keywords
